Post-traumatic chronic seronegative monarthritis responding to antitumor necrosis factor-alpha therapy

References

1. ↵
   1. Currey J,
   2. Therkildsen LH,
   3. Bywaters EG

   (1986) Monarticular rheumatoid-like arthritis of seven years'duration following fracture of the radial head. Ann Rheum Dis 45:783–785.

   OpenUrlAbstract/FREE Full Text
2. ↵
   1. Olivieri I,
   2. Padula A,
   3. D'Angelo S,
   4. Scarpa R

   (2008) Role of Trauma in Psoriatic Arthritis. J Rheumatol 35:2085–2087.

   OpenUrlFREE Full Text
3. ↵
   1. Pattison E,
   2. Harrison BJ,
   3. Griffiths CE,
   4. Silman AJ,
   5. Bruce IN

   (2008) Environmental risk factors for the development of psoriatic arthritis: results from a case-control study. Ann Rheum Dis 67:672–676.

   OpenUrlAbstract/FREE Full Text
4. ↵
   1. The National Institute for Health and Care Excellence (NICE)

   Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed, Available from URL: https://www.nice.org.uk/guidance/ta375. [Update 2016 January 26; Accessed 2018 February 27).